Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic companies, which ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat reports.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), United Therapeutics (UTHR – Research Report) and Universal ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief ...

LGT Fund Management Co Ltd. acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...